Effect of Garlic Supplements on Opioids in Healthy Volunteers
Overview[ - collapse ][ - ]
Purpose | RATIONALE: Garlic supplements may change the effectiveness of oxycodone used to relieve moderate or severe pain. PURPOSE: This randomized phase I trial is studying how garlic supplements may change the effectiveness of opioids in healthy volunteers. |
---|---|
Condition | Healthy, no Evidence of Disease |
Intervention | Dietary Supplement: garlic Drug: digoxin Drug: midazolam hydrochloride Drug: oxycodone hydrochloride Genetic: gene expression analysis Genetic: protein expression analysis Other: laboratory biomarker analysis Other: liquid chromatography Other: mass spectrometry Other: pharmacological study |
Phase | Phase 4 |
Sponsor | Fred Hutchinson Cancer Research Center |
Responsible Party | Fred Hutchinson Cancer Research Center |
ClinicalTrials.gov Identifier | NCT00499460 |
First Received | July 10, 2007 |
Last Updated | April 30, 2012 |
Last verified | April 2012 |
Tracking Information[ + expand ][ + ]
First Received Date | July 10, 2007 |
---|---|
Last Updated Date | April 30, 2012 |
Start Date | November 2006 |
Estimated Primary Completion Date | September 2008 |
Current Primary Outcome Measures | Oxycodone hydrochloride pharmacodynamic measures |
Current Secondary Outcome Measures | Oxycodone hydrochloride pharmacokinetic parameters |
Descriptive Information[ + expand ][ + ]
Brief Title | Effect of Garlic Supplements on Opioids in Healthy Volunteers |
---|---|
Official Title | Modulation of Opioid Effects by Garlic Supplements |
Brief Summary | RATIONALE: Garlic supplements may change the effectiveness of oxycodone used to relieve moderate or severe pain. PURPOSE: This randomized phase I trial is studying how garlic supplements may change the effectiveness of opioids in healthy volunteers. |
Detailed Description | OBJECTIVES: - Determine whether a CYP3A- and P-glycoprotein-dependent interaction exists between garlic supplements and a commonly used oral opioid analgesic (oxycodone hydrochloride) in healthy volunteers. OUTLINE: This is a single-blind, randomized, crossover study. Participants are randomized to 1 of 2 arms. - Arm I: Participants receive oral garlic twice daily on days 1-28 and oral oxycodone hydrochloride on days 2 and 28. Participants then receive oral placebo twice daily on days 58-87 and oral oxycodone hydrochloride on days 60 and 85. - Arm II: Participants receive oral placebo twice daily on days 1-28 and oral oxycodone hydrochloride on days 2 and 28. Participants then receive oral garlic twice daily on days 58-87 and oral oxycodone hydrochloride on days 60-85. In both arms, participants receive oral midazolam hydrochloride and oral digoxin once on days 29 and 86. Blood samples are collected periodically and examined by liquid chromatography-mass spectrometry (LC-MS) for CYP3A4 and P-glycoprotein phenotyping. Blood and urine samples are collected after receiving oxycodone hydrochloride for pharmacokinetic-pharmacodynamic studies via LC-MS. Pain response is assessed at baseline and periodically after oxycodone hydrochloride treatment via electrical stimulation and the cold pressor test. Side effects of oxycodone hydrochloride treatment are assessed via questionnaires and tests for cognitive function, manipulative dexterity, motor speed, and visual attention. |
Study Type | Interventional |
Study Phase | Phase 4 |
Study Design | Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science |
Condition | Healthy, no Evidence of Disease |
Intervention | Dietary Supplement: garlic Drug: digoxin Drug: midazolam hydrochloride Drug: oxycodone hydrochloride Genetic: gene expression analysis Genetic: protein expression analysis Other: laboratory biomarker analysis Other: liquid chromatography Other: mass spectrometry Other: pharmacological study |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 18 |
Estimated Completion Date | September 2008 |
Estimated Primary Completion Date | Not Provided |
Eligibility Criteria | DISEASE CHARACTERISTICS: - Healthy volunteer - Body mass index 20-32 PATIENT CHARACTERISTICS: - Not pregnant - No history of cardiopulmonary, liver, renal, endocrine, neurologic, or psychiatric disease - No anemia - No known adverse reactions to opioids, benzodiazepines, cardiac glycosides, or garlic supplements - No known allergy or hypersensitivity to sulfur-containing food or drugs - No significant gastrointestinal intolerance to lactose in dairy products - No recent history of alcohol or substance abuse - No history of or concurrent heavy daily consumption of allium vegetables (i.e., garlic, shallots, leeks, and chives) - No handicaps due to visual and hearing impairments - No resting heart rate < 50 beats per minutes - No abnormal cardiac rhythm by EKG - No unusually sensitive response or resistance to pain stimulation (cutaneous electrical stimulation and cold pressor test) - Must be right handed - No color blindness - No history of learning disabilities or dyslexia - Must be literate and proficient in English - Must be a nonsmoker PRIOR CONCURRENT THERAPY: - No concurrent medication except oral contraceptives - No concurrent grapefruit or grapefruit juice - No other concurrent over-the-counter herbal products or herbal tea |
Gender | Both |
Ages | 21 Years |
Accepts Healthy Volunteers | Accepts Healthy Volunteers |
Contacts | Not Provided |
Location Countries | United States |
Administrative Information[ + expand ][ + ]
NCT Number | NCT00499460 |
---|---|
Other Study ID Numbers | 2040.00 |
Has Data Monitoring Committee | No |
Information Provided By | Fred Hutchinson Cancer Research Center |
Study Sponsor | Fred Hutchinson Cancer Research Center |
Collaborators | National Cancer Institute (NCI) |
Investigators | Principal Investigator: Danny Shen, PhD Fred Hutchinson Cancer Research Center |
Verification Date | April 2012 |
Locations[ + expand ][ + ]
Fred Hutchinson Cancer Research Center | Seattle, Washington, United States, 98109-1024 |
---|